Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX) and Illumina (ILMN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CytomX Therapeutics (CTMX – Research Report) and Illumina (ILMN – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CytomX Therapeutics (CTMX)
In a report released yesterday, Michael Schmidt from Guggenheim reiterated a Buy rating on CytomX Therapeutics, with a price target of $10.00. The company’s shares closed last Friday at $4.68.
According to TipRanks.com, Schmidt is a 5-star analyst with an average return of
CytomX Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.50, implying a 104.7% upside from current levels. In a report issued on February 26, Barclays also maintained a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Illumina (ILMN)
In a report released yesterday, Kyle Mikson CFA from Canaccord Genuity maintained a Hold rating on Illumina, with a price target of $150.00. The company’s shares closed last Friday at $124.62.
According to TipRanks.com, CFA is a 2-star analyst with an average return of
Currently, the analyst consensus on Illumina is a Hold with an average price target of $129.81, implying a 2.4% upside from current levels. In a report issued on March 2, TipRanks – PerPlexity also downgraded the stock to Hold with a $145.00 price target.
